By Regulatory Approvals — FDA Approves Subcutaneous Risankizumab for Crohn's Disease Gastroenterology & Endoscopy News
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. November 3, 2026.